ARVINAS, INC. — Director's Dealing 2018

Oct 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARVINAS INC. (ARVN)
CIK: 0001655759
Period of Report: 2018-10-01

Reporting Person: Loven Jakob (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-01	Common Stock	P	312500	$16.00	Acquired	312500	Indirect
2018-10-01	Common Stock	C	1381851	—	Acquired	1694351	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-01	Series C Preferred Stock	$	C	4491018	Disposed		Common Stock (1381851)	Indirect

Footnotes

F1: Reflects shares of the Issuer's Common Stock that were purchased in connection with the Issuer's initial public offering.

F2: The shares are held directly by Nextech V Oncology S.C.S., SICAV-SIF. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV-SIF. Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a member of the investment committee of Nextech Invest AG and may be deemed to have shared voting and/or investment power over the shares reported hereby. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

F3: On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.